UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pre-existing anti–polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer

Journal of allergy and clinical immunology, 2016-05, Vol.137 (5), p.1610-1613.e7

2016

Volltextzugriff (PDF)

Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer

Journal of allergy and clinical immunology, 2016-12, Vol.138 (6), p.1712-1715

2016

Volltextzugriff (PDF)

Aptamers: an emerging class of therapeutics

Annual review of medicine, 2005-01, Vol.56 (1), p.555-583

2005

Volltextzugriff (PDF)

Antidote-mediated control of an anticoagulant aptamer in vivo

Nature biotechnology, 2004-11, Vol.22 (11), p.1423-1428

2004

Volltextzugriff (PDF)

First Clinical Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary Intervention

Circulation (New York, N.Y.), 2010-08, Vol.122 (6), p.614-622

2010

Volltextzugriff (PDF)

Coagulation factor IXa as a target for treatment and prophylaxis of venous thromboembolism

Arteriosclerosis, thrombosis, and vascular biology, 2010-03, Vol.30 (3), p.382-387

2010

Volltextzugriff (PDF)

Inhibition of Rat Corneal Angiogenesis by a Nuclease-Resistant RNA Aptamer Specific for Angiopoietin-2

Proceedings of the National Academy of Sciences - PNAS, 2003-04, Vol.100 (9), p.5028-5033

2003

Volltextzugriff (PDF)

Factor IXa inhibitors as novel anticoagulants

Arteriosclerosis, thrombosis, and vascular biology, 2007-04, Vol.27 (4), p.722-727

2007

Volltextzugriff (PDF)

An Anticoagulant RNA Aptamer That Inhibits Proteinase-Cofactor Interactions within Prothrombinase

The Journal of biological chemistry, 2010-02, Vol.285 (8), p.5212-5223

2010

Volltextzugriff (PDF)

To PEGylate or Not To PEGylate Therapeutics?

Cell chemical biology, 2019-05, Vol.26 (5), p.615-616

2019

Volltextzugriff (PDF)

A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: Design and rationale of the RADAR Phase IIb trial

The American heart journal, 2011-02, Vol.161 (2), p.261-268.e2

2011

Volltextzugriff (PDF)

In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry

Thrombosis and haemostasis, 2009-05, Vol.101 (5), p.827-833

2009

Volltextzugriff (PDF)

RNA aptamers as reversible antagonists of coagulation factor IXa

Nature (London), 2002-09, Vol.419 (6902), p.90-94

2002

Volltextzugriff (PDF)

First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology : A phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity

Circulation (New York, N.Y.), 2006-12, Vol.114 (23), p.2490-2497

2006

Volltextzugriff (PDF)

Blocking the initiation of coagulation by RNA aptamers to factor VIIa

Thrombosis and haemostasis, 2000-11, Vol.84 (5), p.841-848

2000

Volltextzugriff (PDF)

SUBCUTANEOUS FIXA INHIBITOR PROVIDES PROLONGED ANTICOAGULATION: THE FIRST SUCCESSFUL SUBCUTANEOUS APPLICATION OF AN APTAMER

Journal of the American College of Cardiology, 2010-03, Vol.55 (10), p.A172.E1618-A172.E1618

2010

Volltextzugriff (PDF)

Phase 1b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients With Stable Coronary Artery Disease

Circulation (New York, N.Y.), 2008-06, Vol.117 (22), p.2865-2874

2008

Volltextzugriff (PDF)

Nucleic acid aptamers as antithrombotic agents: Opportunities in extracellular therapeutics

Thrombosis and haemostasis, 2010-03, Vol.103 (3), p.586-595

2010

Volltextzugriff (PDF)

Direct factor IXa inhibition with the RNA-aptamer pegnivacogin reduces platelet reactivity in vitro and residual platelet aggregation in patients with acute coronary syndromes

European heart journal. Acute cardiovascular care, 2019-09, Vol.8 (6), p.520-526

2019

Volltextzugriff (PDF)

RNA aptamer to thrombin binds anion-binding exosite-2 and alters protease inhibition by heparin-binding serpins

FEBS letters, 2004-06, Vol.568 (1), p.10-14

2004

Volltextzugriff (PDF)

Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy

European heart journal, 2011-10, Vol.32 (19), p.2412-2419

2011

Volltextzugriff (PDF)

The potential of aptamers as anticoagulants

Trends in cardiovascular medicine, 2005, Vol.15 (1), p.41-45

2005

Volltextzugriff (PDF)

Translating Nucleic Acid Aptamers to Antithrombotic Drugs in Cardiovascular Medicine

Journal of cardiovascular translational research, 2010-12, Vol.3 (6), p.704-716

2010

Volltextzugriff (PDF)

Factor IXa as a Target for Pharmacologic Inhibition in Acute Coronary Syndrome

Cardiovascular therapeutics, 2011-08, Vol.29 (4), p.e22-e35

2011

Volltextzugriff (PDF)

Platelet functions beyond hemostasis

Journal of thrombosis and haemostasis, 2009-11, Vol.7 (11), p.1759-1766

2009

Volltextzugriff (PDF)

1 – 25 von 48

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(40)

Publikationsform

Sprache

Englisch
(48)
Japanisch
(9)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Pre-existing anti–polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer

Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer

Aptamers: an emerging class of therapeutics

Antidote-mediated control of an anticoagulant aptamer in vivo

First Clinical Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary Intervention

Coagulation factor IXa as a target for treatment and prophylaxis of venous thromboembolism

Inhibition of Rat Corneal Angiogenesis by a Nuclease-Resistant RNA Aptamer Specific for Angiopoietin-2

Factor IXa inhibitors as novel anticoagulants

An Anticoagulant RNA Aptamer That Inhibits Proteinase-Cofactor Interactions within Prothrombinase

To PEGylate or Not To PEGylate Therapeutics?

A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: Design and rationale of the RADAR Phase IIb trial

In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry

RNA aptamers as reversible antagonists of coagulation factor IXa

First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology : A phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity

Blocking the initiation of coagulation by RNA aptamers to factor VIIa

SUBCUTANEOUS FIXA INHIBITOR PROVIDES PROLONGED ANTICOAGULATION: THE FIRST SUCCESSFUL SUBCUTANEOUS APPLICATION OF AN APTAMER

Phase 1b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients With Stable Coronary Artery Disease

Nucleic acid aptamers as antithrombotic agents: Opportunities in extracellular therapeutics

Direct factor IXa inhibition with the RNA-aptamer pegnivacogin reduces platelet reactivity in vitro and residual platelet aggregation in patients with acute coronary syndromes

RNA aptamer to thrombin binds anion-binding exosite-2 and alters protease inhibition by heparin-binding serpins

Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy

The potential of aptamers as anticoagulants

Translating Nucleic Acid Aptamers to Antithrombotic Drugs in Cardiovascular Medicine

Factor IXa as a Target for Pharmacologic Inhibition in Acute Coronary Syndrome

Platelet functions beyond hemostasis

Suchergebnisse filtern